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Introduction
Acute myeloid leukemia (AML) is a molecularly heterogeneous disease characterized by an expansion of immature blood cells due to impaired self-renewal, differentiation, and apoptosis. High relapse rates, thought to be due to persistence of chemoresistant leukemia cells, and refractoriness to second line chemotherapy remain major therapeutic challenges associated with poor outcomes(1). The leukemic microenvironment has been implicated in chemoresistance and nurturing of leukemiainitiating cells through multiple mechanisms (2) . Recent findings from our group and others (3) (4) (5) demonstrated that hypoxia is a prevalent feature of the leukemic, but not the normal, BM microenvironment. Utilizing murine leukemia models, we showed vast expansion of hypoxia niches within the leukemic BM microenvironment that paralleled leukemia progression. Similarly, hypoxia was shown to be present in multiple myeloma in vivo models and to correlate with disease progression and aggressiveness (3, 4) .
Pathologic hypoxia is a common feature in many solid tumors and is associated with increased tumor aggressiveness and resistance to therapy, mediated at least in part through activation of hypoxia-inducible factor 1α (HIF-1α) (6) (7) (8) . Indeed, in acute lymphoblastic leukemia (ALL) cells, pharmacologic or genetic stabilization of HIF-1α under normoxic conditions inhibited cell growth and reduced apoptosis induction by chemotherapeutic agents, while inhibition of HIF-1α expression promoted chemosensitivity of ALL cells cultured under hypoxic conditions (9) . Our previous data showed that HIF-1α protein was expressed in the BM biopsies of ~60% of Philadelphia chromosome-negative B-ALL patients but was undetectable in normal donor BM, suggesting the importance of HIF-1α in the leukemic BM microenvironment (10) . Matsunaga et al. reported that HIF-1α promotes quiescence of leukemic stem cells residing in the endosteal niches and suggested that this could contribute to minimal residual disease in AML (11) .
HIF-1α induces the expression of an array of genes regulating angiogenesis, invasiveness, drug resistance and glycolysis (12, 13) . Magnetic resonance spectroscopy (MRS) is an analytical technique that allows for non-radioactive isotopes (such as 1 H, 13 C, 31 P) to be detected in a high field magnet. Because nuclei in different chemical environments will have slightly different resonance frequencies, MRS can be used to determine the metabolic profile of biological samples ex vivo or in vivo (14, 15) .
However, real time metabolic imaging is not possible with conventional MRS, which requires the averaging of multiple readings to generate a well resolved spectrum. This problem has been solved by a new method called hyperpolarized MRS, which achieves a >10,000 fold enhancement of signal over conventional MRS, allowing non-toxic and non-radioactive imaging of metabolic products after addition of a hyperpolarized agent to a biological system (16) (17) (18) . Hyperpolarized (HP) 13 C-enriched pyruvate, a novel diagnostic substrate, has been utilized to interrogate glycolytic metabolism in leukemia bearing mice and normal controls in vivo through tracing the metabolism of pyruvate to alanine, lactate and bicarbonate (16) (17) (18) . Under hypoxic conditions, cancer cells re-wire their metabolism by increasing glucose uptake and utilizing anaerobic glycolysis for energy generation. This increase leads to high levels of lactate production through pyruvate being utilized by lactate dehydrogenase. Using hyperpolarized pyruvate technology, the glycolytic flux of lactate dehydrogenase can be monitored in real time. The higher the flux rates, the greater use of glycolysis in that particular tissue.
Research. Hypoxia-activated prodrugs (HAPs) are designed to deliver cytostatic or cytotoxic effects to hypoxic subregions. In most cases, the first step in their activation reaction consists of a one-electron reduction of the prodrug by generally ubiquitous one-electron reductases (19) (20) (21) , resulting in a prodrug radical that undergoes redox cycling in the presence of oxygen (22) . Under hypoxic conditions, the radical has a much longer lifetime and undergoes fragmentation or further reduction, leading to formation of the active drug in hypoxic cells. We have previously shown the effectiveness of HAP PR-104 in preclinical leukemia models, supporting the concept for the selective cytotoxic targeting of the hypoxic leukemic environment (23) , and recently reported the results of the Phase I clinical trial. (24) TH-302 is a HAP that is currently in clinical testing for a broad series of indications, including myeloma and AML/ALL. Upon reduction of a nitro group in TH-302, the prodrug releases a DNA-crosslinking mustard alkylating agent (bromoisophosphoramide) in hypoxic regions (25, 26) . In multiple myeloma models, TH-302 demonstrated profound in vitro and in vivo antitumor activity (27) .
In this study, we characterized the leukemic microenvironment through hypoxiaregulated gene expression studies, dynamic MRS of HP-pyruvate in vivo and interrogation of residual hypoxic leukemia cells surviving chemotherapy using the hypoxia-activated prodrug TH-302. Our findings confirm the premise that hypoxia is a prominent component of leukemia and demonstrate the improved anti-leukemia efficacy of combining traditional therapeutics with hypoxia-targeting agents.
Research. 
Materials and Methods

Chemicals, antibodies, and reagents
TH-302 was provided by Threshold Pharmaceuticals. Cytarabine, doxorubicin, 5-azacytidine, and decitabine were purchased from the pharmacy of The University of Texas MD Anderson Cancer Center. Sorafenib was acquired from Selleckchem.
Fluorescein isothiocyanate-conjugated mouse monoclonal anti-pimonidazole (PIMO) antibody (Hypoxyprobe, Inc.) was used for immunohistochemical (IHC) analysis.
Antibodies used for fluorescence-activated cell sorting (FACS) were AnnexinV-Cy5, mouse anti-human CD45, rat anti-mouse CD45, mouse anti-human CD34, and mouse anti-human CD123 (BD Biosciences). Propidium iodide (PI) and 7-amino-actinomycin D (7AAD) were purchased from Sigma Chemical. 
mRNA hybridization and gene-expression profiling by Nanostring technology
Total RNA was amplified and hybridized to Illumina HT12 version 4 human whole-genome arrays as described previously(28).
For Nanostring analysis, mononuclear cells from BM and peripheral blood samples from patients with acute leukemia or healthy subjects were lysed to isolate total mRNA. For each sample, 100 ng of mRNA was used to set up Nanostring codeset 5; the genes included in the analysis are listed in Supplementary Table S3 .
Magnetic Resonance Imaging
Imaging was performed on a 7-Tesla, 30-cm bore Biospec MR imaging system (Bruker Biospin Corp., Ettlingen, Germany) equipped with a Bruker gradient/shim system BGA- 
Hyperpolarized Magnetic Resonance Spectroscopy
To generate HP-pyruvate, a 26-mg sample of neat [1- 13 C]pyruvic acid (SigmaAldrich), containing 15 mM of OX063 radical (GE Healthcare) and 1.5 mM Prohance (Bracco Diagnostics Inc.), was polarized in a HyperSense DNP system (Oxford Instruments) as previously described (29, 30) . The frozen sample was rapidly dissolved, resulting in a final isotonic and neutral solution containing 80mM [1- 
In vitro TH-302 cytotoxicity assay
Cells were seeded at 1×10 
Detection of hypoxia in BM
Following chemotherapy and TH-302 treatment, hypoxia probe pimonidazole (PIMO) was administered intraperitoneally at 100 mg/kg. Three hours later, mice were euthanized and their femurs and tibiae were processed for IHC.
Statistical analysis
Unless otherwise indicated, results are expressed as mean ± SEM of three independent experiments. P-values were determined by one-way ANOVA followed by F statistics or paired t-test (when comparing two groups). A P-value less than 0.05 was considered significant. Survival analysis for in vivo studies was done using Mantel-Cox and Gehan-Breslow-Wilcoxon tests. Unless otherwise noted, all calculations were carried out by the GraphPad Prism software (GraphPad) software. 
Results
Hypoxia signature expression in leukemia cell lines and primary samples
We previously used chemical probes of hypoxia to detect expansion of hypoxic niches in murine leukemia-bearing BM(5), and additionally found stabilization of HIF-1α in BM from leukemia patients (9) . To elucidate molecular changes associated with the hypoxic nature of the leukemic BM microenvironment, we first established a set of hypoxia-regulated genes in leukemia cells utilizing genome-wide gene expression profiling (GEP). To this end, total RNA from REH or OCI-AML3 human leukemia cell lines, each cultured for 48 h at 21% or 1% O 2 was used for GEP by microarrays. Using strict significance criteria (P value < 0.01, false discovery rate q statistic < 0.1) for three independent experiments, we found 21 genes consistently upregulated by hypoxia in both cell lines (Supplementary Table S3) . From these genes, we selected a "hypoxia set" that included genes known to be regulated by HIF transcription factors and/or that overlap with established hypoxia signatures in solid tumors (31) (32) (33) . Next, we utilized Nanostring probes to compare the hypoxia-related gene expression in samples from leukemia patients (N = 15, Supplementary Table S2) and normal healthy donors (N=4).
The expression of 9 of the 21 genes interrogated, including LDHA, EGLN1, HIF1AN, ARNT and TGFB, was individually significantly different between leukemia patient samples and controls (Fig. 1A) . When expression levels of these 21 genes were 
femur was significantly lower in normal animals compared to those bearing AML ( Fig.   2C ; P < 0.01), indicating higher rates of glycolysis in the leukemic microenvironment in vivo.
In Vitro High Resolution Metabolic Nuclear Magnetic Resonance Analysis
To further explore the metabolic profile of pyruvic acid, in vitro AML/ETO cells were incubated in media containing 1 mM of 1- 
Targeting hypoxia in vitro with TH-302
Given our findings indicating that hypoxia is a prevalent feature of the leukemic BM microenvironment, and because of the known role of hypoxia in tumor biology and chemoresistance, we studied targeting hypoxia in leukemia with the HAP TH-302.We
Research. first tested this agent's antitumor activity in vitro against several leukemic cell lines representing diverse acute leukemia subtypes, including KBM-5 (chronic myeloid leukemia), KG-1, OCI-AML3, MOLM-13 (AML), REH and Nalm-6 (pre-B-ALL). Fig. 3A shows dose-dependent cytotoxicity in the cell lines tested, summarized in Supplementary Table S5 by the median inhibitory concentrations (IC 50 ) for normoxia and hypoxia, and a hypoxia cytotoxicity ratio (HCR) reflecting the hypoxia-selective cell killing. Sensitivity varied across cell lines, but was consistently much greater in hypoxia.
Nalm-6 cells were the most sensitive (IC 50 in normoxia and hypoxia: 1.3 and 0.005μM, respectively). We extended our results to primary ALL (#1 and #2) and AML (#3) samples, which exhibited drug-dependent cytotoxicity under hypoxic but not normoxic conditions (Fig. 3B) . Importantly, TH-302 was able to target the leukemic stem cellenriched CD34+/CD123+ population in a primary AML sample, as shown in Fig. 3C . In contrast, TH-302 exhibited minimal cytotoxic activity against four normal bone marrow samples (Fig. 3D) . Supplementary Fig. 1 ).
Extensive hypoxia was present in the MSC/AML spheroids grown at normal oxygen tension, as revealed by PIMO staining (Supplementary Fig. 2 ). We then determined the anti-leukemia activity of TH-302 in spheroid co-cultures of MSCs plus MOLM-13 or OCI- Fig. 1A, B) .
The anti-leukemia efficacy of TH-302 was next tested in combination with chemotherapy agents frequently used for treatment of AML (cytarabine, doxorubicin) or with demethylating agents 5-azacytidine or decitabine (Supplementary Fig. 3 ). 
Combinations of TH-
In vivo anti-leukemia activity of TH-302
To validate our in vitro observations, we tested the anti-leukemia efficacy of TH- days; TH-302, 28.3 days; sorafenib, 24.6 days; combination, 32 days; Fig. 5A ). The anti-leukemia effects were also evidenced by reduced bioluminescence imaging intensity in the treated groups than in the vehicle-treated animals (Fig. 5B, C) .
AML cells surviving chemotherapy remain hypoxic and can be targeted by TH-302 leading to survival extension
Based on recent evidence suggesting that cancer stem cells reside in hypoxic niches that protect them from chemotherapeutics and are responsible for disease recurrence after treatment(2, 35, 36), we determined whether hypoxia was still present after disease debulking using the AML1/ETO syngeneic leukemia model. On day 18 after transplantation when engraftment was confirmed by detection of circulating GFP+ cells by FACS, mice were randomized and treated with vehicle or chemotherapy (cytarabine plus doxorubicin, DA) for 5 days. Treatment was effective in reducing circulating GFP-positive cells (controls, 11.5 ± 4.9, N = 6; treatment, 0.52 ± 0.27, N=8; Fig. 6A ), mimicking the disease in humans. To determine the persistence of hypoxia, mice were administered the hypoxia marker PIMO one week after completion of AD chemotherapy and sacrificed. Immunohistochemical staining of the BM from these mice revealed that while hypoxia was greatly expanded in control mice with high leukemia burden, it persisted in residual cells surviving chemotherapy (Fig. 6B) . Figures 6A, B) .
Discussion
The results shown in this work highlight hypoxia's role as a major feature of the microenvironment. Gene expression profiling of peripheral blood and BM samples from healthy donors and patients with leukemia demonstrated that patients with leukemia have greater "hypoxia signature" expression than controls. The fact that this difference was identifiable even in peripheral blood suggests that the expansion of the hypoxic niche that we and others have described as a common phenomenon of acute BM disease translates into long-lasting gene expression changes in cells that are influenced by the microenvironment. Among the genes that were differentially expressed were the two negative regulators of HIF-1α:EGLN1 and HIFAN; and genes involved in glycolytic metabolism LDHA and PGK1. In agreement with our findings, Rapin et al., recently reported common transcriptional programs in AML patients that included a striking upregulation of the hypoxic response gene signature (37) . These transcriptome changes can lead to, or reflect, metabolic reprogramming of cells. A clear link between hypoxia and glycolysis has been established, whereby hypoxia-induced HIF-1α promotes the expression of several enzymes involved in glycolytic pathways (12, 38, 39) . In vivo metabolic imaging of the BM has proven to be challenging because of technical and anatomical limitations. However, development of noninvasive hyperpolarized 13 C MR, providing 10,000-fold signal amplification over conventional MR, made possible interrogation of the in vivo glycolytic metabolic status of the BM (29, 40, 41) . Utilizing HP- 13 C pyruvate, we found a higher glycolytic rate in murine leukemic BM compared to healthy marrow, as indicated by the greater conversion of pyruvate to lactate. We have preliminary data that the pyruvate conversion to lactate could be occurring primarily in 
the stromal cells compared to the AML/ETO cells (data not shown). This is consistent
with recent publications indicating that increased glycolysis could be caused by stromal cells in close proximity to cancer cells and that there is metabolic crosstalk between the two cell types (42) (43) (44) (45) . This finding provides yet another piece of evidence supporting the metabolic re-programming of BM niches as a consequence of reduced oxygen availability in diseased BM.
The mechanism for hypoxia development in the leukemic BM remains elusive.
Our working hypothesis is that leukemic blasts are intrinsically hypoxic because their high rate of proliferation depletes oxygen rapidly. Although not addressed in the present work, it has been speculated that a defective vasculature in the diseased BM might also models. Most importantly, we found that administration of TH-302 a week after chemotherapy treatment to mice with minimal residual disease prolonged survival, suggesting that this approach may be suitable for eliminating chemotherapy-resistant leukemia-initiating cells. In addition, we determined that residual leukemic BM cells in a syngeneic AML model remain hypoxic after chemotherapy; and that TH-302 selectively reduces hypoxia in AML marrows. We also demonstrated that TH-302 has synergistic and additive effects in combination with conventional chemotherapy and demethylating agents in vitro, as has been observed in preclinical solid tumor models (55) . In line with the in vitro data, we also showed that TH-302 has potent activity in combination with sorafenib in the aggressive MOLM-13 FLT3/ITD in vivo model. The data included in Figure 3D indicate only minor toxicity against normal hematopoietic cells. Yet, we believe that one can expect some degree of myelosupression as on-target side effect of HAPs, which could be in particular apparent in combinations with other cytotoxic agents.
In clinical trials with TH-302 moderate myelosuppression was observed but this did not constitute dose limiting toxicity (DLT). When TH-302 was combined with other myelosuppressive agents as part of a combination regimen in the clinical trials (e.g. TH-302 plus doxorubicin for soft tissue sarcoma) more myelosuppression was observed than what could be expected with doxorubicin alone, but this was not dose limiting. (56) In summary, the work presented here extends our understanding of the hypoxic nature of the leukemic BM microenvironment. Our in vivo and in vitro metabolic data offer hints on the metabolic rewiring occurring in the diseased marrow and provide additional "metabolic" therapeutic targets. We showed that HAPs can be utilized and peripheral blood (PB, n=12) samples from patients with AML (N=15) and healthy subjects (PB n=2, BM n=2) were collected during routine diagnostic procedures and subjected to Nanostring analysis. A. Genes whose expression in AML samples was significantly different than that in normal samples. B. Hypoxia signature index (calculated for each sample by averaging the relative expression of all genes with detectable levels) in samples from healthy donors and patients with AML. P-value was calculated using unpaired t-test with Welch's correction. 
